News Search Results
Oct 31, 2025, 13:51 ET Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain receive the 2025 Merkin Prize at the Broad Institute for chimeric antigen receptor (CAR) T-cell therapy
announced as winners in May for pioneering CAR T-cell therapy, a technology that has reshaped how physicians treat leukemia, lymphoma, and multiple myeloma — and is now showing promise in treating autoimmune and infectious diseases [
More news about: Broad Institute
Oct 31, 2025, 07:49 ET AbbVie Reports Third-Quarter 2025 Financial Results
monitoring patients in the outpatient setting for the first full dose of Epkinly (epcoritamab) monotherapy in adult patients with R/R diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy. Results from the study demonstrated that the incidence and severity of cytokine
More news about: AbbVie
Oct 30, 2025, 16:54 ET BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M
includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed
More news about: BioVaxys Technology Corp.
Oct 30, 2025, 16:00 ET Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025
available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia
More news about: Curis, Inc.
Oct 30, 2025, 07:35 ET Knight Therapeutics anuncia la aprobación y el lanzamiento de MINJUVI® (tafasitamab) en Argentina
Diffuse Large B-Cell Lymphoma. Am Soc Clin Oncol Educ Book. 2023 Jan;43:e390802 Duell, J et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021
More news about: Knight Therapeutics Inc.
Oct 29, 2025, 15:25 ET Eminent Physician-Scientist Dr. Jonathan D. Licht to Serve as Next President and Chief Scientific Officer of Van Andel Institute
2023. Licht's laboratory studies how epigenetic errors contribute to development of blood malignancies, including leukemia, lymphoma and myeloma, with the goal of developing treatments to reverse these processes. His many contributions include identifying mutations that contribute
More news about: Van Andel Institute
Oct 29, 2025, 08:11 ET AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin
More news about: AbbVie
Oct 28, 2025, 17:31 ET CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
treatment practices, addressable patient population, which includes top indications such as Acute Lymphoblastic Leukemia, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Multiple Myeloma, Glioblastoma Multiforme, Systemic Lupus Erythematosus, Myasthenia Gravis, Lupus Nephritis, Multiple Sclerosis, and
More news about: DelveInsight Business Research, LLP
Oct 28, 2025, 11:00 ET Rawlings® Presents Heart of Gold Award™ to Mattingly Charities for Outstanding Commitment to Underserved Youth
Foundation) 2019: Curtis Granderson (Curtis Granderson Foundation) 2023: Liam Hendriks (Hendriks Heros, Lymphoma Research Foundation) 2024: Aaron Judge (All Rise Foundation)
More news about: Rawlings
Oct 28, 2025, 07:00 ET BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed
More news about: BioVaxys Technology Corp.
Oct 27, 2025, 13:12 ET The Inner Circle acknowledges Dr. Yasmen Helen Simonian, as a Pinnacle Professional Member Inner Circle of Excellence
both an educator and a leader. Beyond her university responsibilities, Dr. Simonian serves on the boards of the Leukemia & Lymphoma Society and the American Cancer Society. She is a fellow of the Association of Schools of Advancing Health Professions and a member of the American
More news about: The Inner Circle
Oct 27, 2025, 08:00 ET Prime Therapeutics to present latest managed care pharmacy insights at AMCP Nexus 2025
Care and Adverse Effects Assessment of Bispecific T-cell Engagers and Chimeric Antigen Receptor T-cell Therapies for Relapsed Refractory Follicular Lymphoma The GLP-1 persistence studies take an in-depth look at
More news about: Prime Therapeutics
Oct 27, 2025, 07:15 ET ADC Therapeutics to Present at November Investor Conferences
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In
More news about: ADC Therapeutics SA
Oct 27, 2025, 07:15 ET Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Oct 27, 2025, 07:00 ET Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Oct 27, 2025, 06:41 ET Antibody-Drug Conjugates Market to Surge to US $30.42 Billion by 2033, Fueled by Next-Gen Targeted Oncology Therapies | According to DataM Intelligence
commanding nearly 35–40% of total ADC revenues due to the widespread adoption of HER2-targeting agents. However, blood cancers such as lymphoma and leukemia are rapidly catching up, driven by approvals of drugs like Adcetris and Polivy. Emerging applications
More news about: DataM Intelligence 4 Market Research LLP
Oct 24, 2025, 06:45 ET Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
immune system problems. Olumiant may increase your risk of lymphoma and other cancers, including skin cancers. People taking a medicine in the class of medicines called JAK inhibitors have a higher risk of certain cancers, including lymphoma and lung cancer, especially if you are a current or past smoker.
More news about: Eli Lilly and Company
Oct 23, 2025, 19:30 ET HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
Encouraging antitumor activity: Two confirmed partial responses (PRs) in head and neck squamous cell carcinoma (HNSCC) and non-Hodgkin lymphoma, alongside durable disease control in multiple patients. "The presentation of HCB101 data at FACO 2025
More news about: HanchorBio Inc.
Oct 23, 2025, 07:00 ET HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology
therapeutic window. Early signs of efficacy included two confirmed partial responses (PRs) in head and neck squamous cell carcinoma and marginal zone lymphoma, along with stable disease (SD) in nine patients, including over 40 weeks of disease control in platinum-resistant ovarian cancer.
More news about: HanchorBio Inc.
Oct 23, 2025, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
and Cancer Therapeutics: NSCLC bearing the EML4-ALK fusion (Echinoderm microtubule-associated protein-like 4- Anaplastic Lymphoma Kinase) occurs in approximately 5% of NSCLC. Tumors bearing the fusion are sensitive to ALK Tyrosine Kinase Inhibitors (TKIs), that form the first
More news about: Genprex, Inc.
Oct 22, 2025, 03:45 ET BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed
More news about: BioVaxys Technology Corp.
Oct 21, 2025, 16:30 ET Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related
More news about: Citius Pharmaceuticals, Inc.
Oct 21, 2025, 09:00 ET SciTech Development Strengthens Leadership Team with Appointment of Dr. Peter Littrup as Medical Director and Joseph Kraus to Advisory Board
safety. Its lead candidate, ST-001 nanoFenretinide™, a first-in-class therapeutic currently in clinical trials for T-cell Non-Hodgkin Lymphoma, has demonstrated a strong safety profile and promising efficacy. ST-001 is now advancing toward a Small Cell Lung Cancer trial and shows
More news about: SciTech Development, Inc.
Oct 21, 2025, 08:49 ET Pvolve Awards New Studio to Helena Beckett in Monterey, California
numerous endurance events, including triathlons, half marathons and multi-day cycling rides, to raise funds for causes such as the Leukemia & Lymphoma Society and school nutrition programs. "I first discovered Pvolve through a Jennifer Aniston ad on Instagram," Beckett said.
More news about: Pvolve
Oct 21, 2025, 08:05 ET The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher,
More news about: Institute for Follicular Lymphoma Innovation (IFLI)